Drug-eluting stent thrombosis.
Drug-eluting stents (DES) have reduced the risk of repeat revascularization procedures by 50-70% compared with bare metal stents across a wide range of lesion and patients subsets. Stent thrombosis is a rare but devastating adverse event, which results in abrupt closure of the treated artery with the incumbent risk of sudden death or myocardial infarction. Although stent thrombosis has been recognized as a shortcoming of coronary artery stents since there inception, very late stent thrombosis occurring more than one year after stent implantation emerged as a new entity complicating the use of DES. The mechanisms leading to very late ST are complex and only incompletely understood. Delayed healing and incomplete re-endothelialization emerged as prevailing mechanism of thrombosis in autopsy studies. Various components of DES may give rise to very late stent thrombosis, notably the polymers used for controlled drug-release. Newer generation DES attempt to address these concerns by aiming at improved vascular healing while maintaining potent neointimal suppression.
Department of Cardiology, Bern University Hospital, Bern, Switzerland.
T
T
Pilgrim
S
S
Windecker
D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D011474:Prosthesis Design; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology